Gabriel Plotkin Ligand Pharmaceuticals Inc Transaction History
Melvin Capital Management LP
- $0
- Q3 2023
A detailed history of Gabriel Plotkin (Melvin Capital Management LP) transactions in Ligand Pharmaceuticals Inc stock. As of the latest transaction made, Melvin Capital Management LP holds 900,000 shares of LGND stock, worth $98.7 Million. This represents 25.41% of its overall portfolio holdings.
Number of Shares
900,000Holding current value
$98.7 Million% of portfolio
25.41%Shares
0 transactions
| Quarter | Operation | Price Per share | shares change | shares Held | SEC Form |
|---|
Others Institutions Holding LGND
# of Institutions
276Shares Held
18.5MCall Options Held
30.8KPut Options Held
5.2K-
Black Rock Inc. New York, NY2.87MShares$315 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA2.09MShares$229 Million0.0% of portfolio
-
Janus Henderson Group PLC London, X01.02MShares$111 Million0.06% of portfolio
-
Macquarie Group LTD Australia, C3884KShares$97 Million0.11% of portfolio
-
State Street Corp Boston, MA744KShares$81.6 Million0.0% of portfolio
About LIGAND PHARMACEUTICALS INC
- Ticker LGND
- Exchange OTC
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 16,882,800
- Market Cap $1.85B
- Description
- Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...